GlobeImmune clinical trials
Acquired by ImmunityBio, Inc., Mar 9, 2021 · source ↗
The registry lists 4 studies whose lead sponsor is GlobeImmune. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 6, 2015.
Before and after it joined ImmunityBio, Inc.
- First submitted before GlobeImmune became part of ImmunityBio, Inc.
- 4
- First submitted after GlobeImmune became part of ImmunityBio, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- GlobeImmune4 studies
Something wrong with this grouping? Tell us on the ImmunityBio, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All ImmunityBio, Inc. studies →
- Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas CancerCompletedNCT00300950Phase 2
Sponsor listed in the registry: GlobeImmune · First submitted before GlobeImmune became part of ImmunityBio, Inc.
- Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C InfectionCompletedNCT00606086Phase 2
Sponsor listed in the registry: GlobeImmune · First submitted before GlobeImmune became part of ImmunityBio, Inc.
- A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras MutationCompletedNCT00655161Phase 2
Sponsor listed in the registry: GlobeImmune · First submitted before GlobeImmune became part of ImmunityBio, Inc.
- Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C InfectionCompletedNCT00124215Phase 1
Sponsor listed in the registry: GlobeImmune · First submitted before GlobeImmune became part of ImmunityBio, Inc.